Legacy Capital Partners Inc. held its stake in NeoGenomics, Inc. (NASDAQ:NEO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 54,800 shares of the medical research company’s stock at the end of the second quarter. Legacy Capital Partners Inc. owned approximately 0.07% of NeoGenomics worth $491,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Cutler Group LP boosted its position in NeoGenomics by 15.9% in the first quarter. Cutler Group LP now owns 13,087 shares of the medical research company’s stock worth $103,000 after buying an additional 1,800 shares during the period. Cambridge Investment Research Advisors Inc. boosted its position in NeoGenomics by 7.9% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,600 shares of the medical research company’s stock worth $107,000 after buying an additional 1,000 shares during the period. Campbell & CO Investment Adviser LLC boosted its position in NeoGenomics by 10.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 15,009 shares of the medical research company’s stock worth $118,000 after buying an additional 1,419 shares during the period. KCG Holdings Inc. bought a new position in NeoGenomics during the first quarter worth approximately $118,000. Finally, OLD National Bancorp IN bought a new position in NeoGenomics during the second quarter worth approximately $141,000. 78.31% of the stock is owned by institutional investors and hedge funds.

NeoGenomics, Inc. (NASDAQ:NEO) opened at 9.31 on Wednesday. NeoGenomics, Inc. has a one year low of $6.90 and a one year high of $9.93. The company has a 50-day moving average of $8.99 and a 200-day moving average of $8.19. The company’s market cap is $737.70 million.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.03. The company had revenue of $66.09 million during the quarter, compared to the consensus estimate of $62.95 million. NeoGenomics had a positive return on equity of 6.02% and a negative net margin of 2.81%. NeoGenomics’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.04 EPS. Equities research analysts expect that NeoGenomics, Inc. will post $0.18 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/neogenomics-inc-nasdaqneo-position-held-by-legacy-capital-partners-inc.html.

A number of research firms have recently commented on NEO. ValuEngine raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Monday. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Saturday, July 29th. BidaskClub cut shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Cantor Fitzgerald set a $11.00 target price on shares of NeoGenomics and gave the stock a “buy” rating in a report on Saturday, May 27th. Finally, BTIG Research reissued a “buy” rating and issued a $11.00 target price on shares of NeoGenomics in a report on Sunday, May 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.40.

In related news, VP Jennifer Balliet sold 3,334 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $7.50, for a total value of $25,005.00. Following the completion of the sale, the vice president now owns 10,049 shares in the company, valued at approximately $75,367.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alison L. Hannah bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average price of $9.19 per share, with a total value of $183,800.00. Following the transaction, the director now directly owns 38,782 shares in the company, valued at $356,406.58. The disclosure for this purchase can be found here. Insiders sold a total of 84,890 shares of company stock valued at $665,707 in the last 90 days. 12.20% of the stock is currently owned by corporate insiders.

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.